Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (2779)	3/17/1998 9:32:00 AM
From: clochard	Read Replies (1) \| Respond to of 7041

Since options expire on Friday, I bet this dog and many others will tank on Monday.

To: Linda Kaplan who wrote (2779)	3/17/1998 10:36:00 AM
From: Dauntless	Read Replies (3) \| Respond to of 7041

Linda, it's not personal I'm sure all you said about Cacaito is true. He may not have a position in Zona but perhaps he has one in a competitor. His profile shows quite a few posts on the Vivus thread. It just seemed clear to me that his post was intended as some kind of a slight towards Zonagen. Point is, why do so many keep dragging out old, irrelevant information in an effort to malign this company. The study he referenced is OLD NEWS - it can, on superficial examination, be seen as casting doubt on the viability of Phentolamine for ED. Other interpretations could be taken as positive (see Bruce's response). There are more recent, and better designed, phase III studies that more accurately address this point. If I missed something here then I apologize to Cacaito. This is just getting so silly - let the professionals involved, Zona, SGP, patent office, FDA, etc. do their work. Hopefully, significant news will be forthcoming soon and we can move beyond the "alternative" motives of some recent posters on this thread.